| Autor: |
Gennaro Gadaleta-Caldarola, Laura Lanotte, Stefania Infusino, Arianna Gadaleta-Caldarola, Francesca Matilde Schipilliti, Claudia Citrigno, Cataldo Petrarota, Antonio Cusmai, Alessandro Rizzo |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
Cancer Treatment and Research Communications, Vol 37, Iss , Pp 100775- (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2468-2942 |
| DOI: |
10.1016/j.ctarc.2023.100775 |
| Popis: |
Background: TROP-2 is emerging as a valid and fruitful strategy in triple-negative breast cancer (TNBC) patients, and several agents are currently under evaluation, including Datopotamab deruxtecan (Dato-DXd). Research design and methods: Herein, we performed a meta-analysis aimed to evaluate any grade adverse events, grade 3-4 adverse events, dose reduction, and serious adverse events in TNBC patients treated with Dato-DXd in clinical trials. Results: The pooled results suggests that Dato-DXd is associated with a favorable safety profile: while any grade treatment-related toxicities were common, grade 3-4 events were not particularly frequent and mainly represented by stomatitis (13.88%; 95% CI, 10.68 – 17.09). Conclusions: These findings may help to comprehensively define the safety profile of Dato-DXd and to assist in the design of future clinical trials in this setting. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
Full Text from ScienceDirect